Incyte Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Incyte yıllık ortalama 16.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual. Gelirler growing yılda ortalama 12.5% oranında artmaktadır. Incyte'in özkaynak karlılığı 1% ve net marjı 0.8%'dir.

Anahtar bilgiler

16.9%

Kazanç büyüme oranı

16.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	12.5%
Özkaynak getirisi	1.0%
Net Marj	0.8%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07

Recent updates

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Feb 02

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Oct 31

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Gelir ve Gider Dağılımı

Incyte nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:INCY Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	4,076	32	1,207
30 Jun 24	3,857	97	1,165
31 Mar 24	3,768	745	1,143
31 Dec 23	3,696	598	1,159
30 Sep 23	3,609	425	1,138
30 Jun 23	3,513	366	1,136
31 Mar 23	3,470	324	1,105
31 Dec 22	3,395	341	999
30 Sep 22	3,331	876	954
30 Jun 22	3,320	945	879
31 Mar 22	3,115	933	796
31 Dec 21	2,986	949	741
30 Sep 21	2,913	535	682
30 Jun 21	2,721	338	612
31 Mar 21	2,703	478	561
31 Dec 20	2,667	-296	518
30 Sep 20	2,457	-335	487
30 Jun 20	2,388	-191	469
31 Mar 20	2,229	-376	457
31 Dec 19	2,159	447	469
30 Sep 19	2,108	405	441
30 Jun 19	2,006	306	435
31 Mar 19	1,997	253	437
31 Dec 18	1,882	109	435
30 Sep 18	1,798	-109	424
30 Jun 18	1,729	-102	419
31 Mar 18	1,534	-167	401
31 Dec 17	1,536	-313	367
30 Sep 17	1,419	-155	363
30 Jun 17	1,306	-154	348
31 Mar 17	1,226	-107	324
31 Dec 16	1,106	104	302
30 Sep 16	1,023	151	260
30 Jun 16	941	74	231
31 Mar 16	858	49	216
31 Dec 15	754	7	197
30 Sep 15	634	-86	193
30 Jun 15	644	13	184
31 Mar 15	581	-33	174
31 Dec 14	511	-48	166
30 Sep 14	485	-54	155
30 Jun 14	372	-136	142
31 Mar 14	374	-101	125
31 Dec 13	355	-83	110

Kaliteli Kazançlar: INCY büyük bir tek seferlik kazanç ile $121.4M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: INCY 'nin mevcut net kar marjları (0.8%) geçen yılın (11.8%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: INCY şirketinin kazancı son 5 yılda yılda 16.9% oranında arttı.

Büyüme Hızlandırma: INCY 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: INCY geçtiğimiz yıl negatif kazanç büyümesine ( -92.4% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( -2.3% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: INCY 'nin Özsermaye Getirisi ( 1% ) düşük olarak değerlendiriliyor.

Incyte Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 13%

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today